#1 Clinical Trials Search in Europe

Trastuzumab Emtansine

Trastuzumab Emtansine, also known as T-DM1 or Kadcyla, is an antibody-drug conjugate being studied in clinical trials for various types of cancer. This article summarizes key information about ongoing and completed trials investigating the efficacy and safety of Trastuzumab Emtansine in breast cancer, gastric cancer, lung cancer, colorectal cancer, and other solid tumors.

Table of Contents

What is Trastuzumab Emtansine?

Trastuzumab Emtansine is a specialized cancer medication that combines two powerful components: trastuzumab and emtansine. It’s also known by other names such as T-DM1, Kadcyla, or ado-trastuzumab emtansine[1]. This drug is part of a class of medications called antibody-drug conjugates, which are designed to deliver cancer-fighting substances directly to tumor cells while minimizing damage to healthy cells[2].

How Does It Work?

Trastuzumab Emtansine works in a unique way:

  • Targeting: The trastuzumab part of the drug targets a protein called HER2 (Human Epidermal Growth Factor Receptor 2) that is found in high amounts on some cancer cells.
  • Delivery: Once the drug attaches to HER2 on the cancer cell, it is taken inside the cell.
  • Cell Destruction: Inside the cell, the emtansine part is released. This is a potent substance that disrupts the cell’s internal structures, leading to cell death.

This targeted approach allows the medication to attack cancer cells while generally sparing healthy cells that don’t have high levels of HER2[3].

What Conditions Does Trastuzumab Emtansine Treat?

Trastuzumab Emtansine is primarily used to treat certain types of cancer that have high levels of HER2. These include:

  • Breast Cancer: It’s used for HER2-positive breast cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body)[1].
  • Gastric (Stomach) Cancer: Some studies have explored its use in HER2-positive advanced gastric cancer[2].
  • Colorectal Cancer: Research is ongoing for its potential use in HER2-positive metastatic colorectal cancer[4].
  • Non-Small Cell Lung Cancer: Clinical trials have investigated its effectiveness in certain types of lung cancer[5].

It’s important to note that Trastuzumab Emtansine is often used after other treatments have been tried, especially in breast cancer cases where previous therapies including trastuzumab (Herceptin) have not been successful[6].

How is Trastuzumab Emtansine Administered?

Trastuzumab Emtansine is given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The typical dosing schedule is:

  • 3.6 milligrams per kilogram of body weight
  • Given once every 3 weeks (21-day cycles)
  • Treatment continues until the disease progresses or unacceptable side effects occur

The infusion usually takes about 30-90 minutes for the first dose, and may be shorter for subsequent doses if well-tolerated. Your healthcare team will monitor you closely during and after each infusion[1][2].

Effectiveness of Trastuzumab Emtansine

Clinical trials have shown promising results for Trastuzumab Emtansine in various cancers:

  • Breast Cancer: In patients with HER2-positive breast cancer who had residual disease after initial treatment, Trastuzumab Emtansine significantly improved invasive disease-free survival compared to standard treatment[7].
  • Gastric Cancer: While results have been mixed, some patients with HER2-positive advanced gastric cancer have shown responses to the treatment[2].
  • Other Cancers: Research is ongoing to determine its effectiveness in colorectal, lung, and other HER2-positive cancers[4][5].

It’s important to remember that the effectiveness can vary from person to person, and your doctor will consider many factors when deciding if Trastuzumab Emtansine is right for you.

Side Effects and Safety Considerations

Like all medications, Trastuzumab Emtansine can cause side effects. Common side effects may include:

  • Fatigue
  • Nausea
  • Muscle or joint pain
  • Headache
  • Constipation or diarrhea
  • Decreased platelet count (which can increase risk of bleeding)

More serious side effects, though less common, can include:

  • Liver problems
  • Heart problems
  • Lung problems
  • Severe skin reactions

Your healthcare team will monitor you closely for these side effects and may adjust your treatment if necessary. It’s crucial to report any new symptoms or changes in your health to your doctor promptly[6][8].

Ongoing Research and Future Directions

Researchers continue to study Trastuzumab Emtansine to understand its full potential and optimize its use. Current areas of investigation include:

  • Its effectiveness in earlier stages of breast cancer[7]
  • Its use in combination with other cancer treatments
  • Its potential in treating other types of HER2-positive cancers[9]
  • Identifying biomarkers that can predict which patients will respond best to the treatment

These ongoing studies aim to refine the use of Trastuzumab Emtansine and potentially expand its benefits to more patients in the future.

Cancer Type Key Findings Common Dosage Notable Side Effects
HER2-positive Breast Cancer Improved PFS and OS in some trials; effective in neoadjuvant and metastatic settings 3.6 mg/kg IV every 3 weeks Thrombocytopenia, hepatotoxicity, neuropathy
HER2-positive Gastric Cancer Mixed results; some benefit in previously treated patients 2.4 mg/kg IV weekly or 3.6 mg/kg IV every 3 weeks Fatigue, nausea, anemia
HER2-positive Non-Small Cell Lung Cancer Modest activity; further research needed 3.6 mg/kg IV every 3 weeks Infusion-related reactions, pneumonitis
HER2-positive Colorectal Cancer Potential benefit after progression on other HER2-targeted therapies 3.6 mg/kg IV every 3 weeks Gastrointestinal and hematologic toxicities
Other Solid Tumors Exploratory studies ongoing; efficacy varies by tumor type 2.4-3.6 mg/kg IV weekly or every 3 weeks Similar to other indications; toxicity profile being evaluated

FAQ

  • What is Trastuzumab Emtansine? Trastuzumab Emtansine is an antibody-drug conjugate that combines trastuzumab (Herceptin) with the cytotoxic agent DM1. It targets HER2-positive cancer cells to deliver the chemotherapy directly to the tumor.
  • What types of cancer is Trastuzumab Emtansine being studied for? Clinical trials are investigating Trastuzumab Emtansine for HER2-positive breast cancer, gastric cancer, non-small cell lung cancer, colorectal cancer, urothelial bladder cancer, pancreatic cancer, and cholangiocarcinoma.
  • How is Trastuzumab Emtansine administered? Trastuzumab Emtansine is typically administered intravenously every 3 weeks at a dose of 3.6 mg/kg. Some trials are also studying weekly dosing at 2.4 mg/kg.
  • What are some common side effects of Trastuzumab Emtansine? Common side effects may include fatigue, nausea, muscle pain, headache, and liver problems. Serious side effects can include heart problems, lung problems, and low platelet counts.
  • How effective is Trastuzumab Emtansine in clinical trials? Efficacy varies by cancer type and trial, but some studies have shown promising response rates and improvements in progression-free survival compared to standard treatments, particularly in HER2-positive breast cancer.

Ongoing Clinical Trials on Trastuzumab Emtansine

  • Study evaluating HER2DX-guided treatment in patients with early-stage HER2-positive breast cancer using trastuzumab, pertuzumab and combination chemotherapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Ireland Spain

  • Study of 89Zr-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium The Netherlands

  • Study on Trastuzumab Emtansine, Pertuzumab, and Atezolizumab for Patients with HER2-Positive Metastatic Cancer Who Benefited from Previous Treatment

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Poland Portugal Spain

  • Study to Determine the Best Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Patients with Advanced HER2+ Metastatic Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy Spain

  • Study on Reducing Treatment for Patients with HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination After 2 Years of Controlled Disease

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • A study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Spain

  • A study of Zr89-trastuzumab PET/CT imaging and trastuzumab emtansine treatment in patients with advanced HER2-positive breast cancer

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study of Atezolizumab, Pertuzumab, and Trastuzumab for Patients with HER2 Positive Early High-Risk and Locally Advanced Breast Cancer

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Germany Italy Romania Spain

  • Study of Tucatinib and Ado-Trastuzumab Emtansine for Patients with Advanced HER2+ Breast Cancer

    Not recruiting

    3 1 1
    Investigated drugs:
    Belgium Denmark France Germany Italy The Netherlands +2

  • Study on Chemotherapy-Free Treatment with Trastuzumab, Pertuzumab, and T-DM1 for Patients with HER2-Positive Early-Stage Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Italy Spain

Glossary

  • Antibody-drug conjugate: A type of targeted cancer therapy that combines a monoclonal antibody with a cytotoxic drug, allowing for more precise delivery of chemotherapy to cancer cells.
  • HER2: Human epidermal growth factor receptor 2, a protein that promotes cancer cell growth when overexpressed. HER2-positive cancers may be treated with HER2-targeted therapies.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without the disease worsening.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor before surgery.
  • Adjuvant therapy: Treatment given after the main treatment to lower the risk of cancer coming back.
  • Metastatic cancer: Cancer that has spread from its original site to other parts of the body.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.

References

  1. https://clinicaltrials.gov/study/NCT02725541
  2. https://clinicaltrials.gov/study/NCT01641939
  3. https://clinicaltrials.gov/study/NCT03153163
  4. https://clinicaltrials.gov/study/NCT03418558
  5. https://clinicaltrials.gov/study/NCT02289833
  6. https://clinicaltrials.gov/study/NCT01702571
  7. https://clinicaltrials.gov/study/NCT01772472
  8. https://clinicaltrials.gov/study/NCT05945927
  9. https://clinicaltrials.gov/study/NCT02999672